Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Chief Legal Officer, CCO & Sec | July 07, 2020 | July 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date July 07, 2020 · Filed July 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-07-07 · Sale · Disposed 941 · Balance 0 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2: Includes 941 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: Includes 941 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2020 Filed Jul 9, 2020 21:43 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 941 | $22.50 | $21,172.50 |
DisclosureSEC source: 0001209191-20-042007 · doc4.xml · nonDerivative · entry 1 Walker Robin A. · CIK 0001790807 · Chief Legal Officer, CCO & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: Includes 941 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 22:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-20-021322 · doc4.xml · derivative · entry 1 Walker Robin A. · CIK 0001790807 · Chief Legal Officer, CCO & Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 22:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 84,800 | $0.00 Strike: $23.32 | $0.00 |
DisclosureSEC source: 0001567619-19-021771 · doc1.xml · derivative · entry 1 Walker Robin A. · CIK 0001790807 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,800 Underlying: Common Stock · 84,800 shares Expires 2029-11-14 F1 · derivative.exercise_date: This option shall vest and become exercisable over a 4 year period: 25% of the total shares shall vest on November 12, 2020 and 1/48th of the total shares shall vest and become exercisable on the monthly anniversary thereafter, subject to reporting person's continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.